Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Rucaparib Camsylate

FDA-approved product (tablet, oral), marketed as Rubraca.

Registered studies
7
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Rucaparib Camsylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Neoplasm
  • Ovarian cancer
  • Ovarian carcinoma
  • Ovarian neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Poly (adp-ribose) polymerase (parp) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli32.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

7registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Rucaparib Camsylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Rucaparib Camsylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy

    NCT04455750 · start 2021-10-14

    Registered record
    Registry ID
    NCT04455750
    Conditions
    Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8
    Interventions
    Enzalutamide; Rucaparib camsylate; Placebo; Leuprolide Acetate; Goserelin Acetate; Degarelix; Quality-of-Life Assessment; Questionnaire Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-10-14
    Completion
    2027-09
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8 +1 more
    InterventionEnzalutamide; Rucaparib camsylate; Placebo; Leuprolide Acetate +4 more
    PhasePhase 3
    Registry statusActive not recruiting

  • A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

    NCT04171700 · start 2020-01-16

    Registered record
    Registry ID
    NCT04171700
    Conditions
    Solid Tumor
    Interventions
    Rucaparib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2020-01-16
    Completion
    2022-07-15
    Enrolment
    83

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumor
    InterventionRucaparib
    PhasePhase 2
    Registry statusTerminated

  • Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

    NCT03442556 · start 2018-08-24

    Registered record
    Registry ID
    NCT03442556
    Conditions
    ATM Gene Mutation; BRCA1 Gene Mutation; BRCA2 Gene Mutation; Castration Levels of Testosterone; Castration-Resistant Prostate Carcinoma; Homologous Recombination Deficiency; Prostate Carcinoma Metastatic in the Bone; PSA Level Greater Than or Equal to Two; PSA Progression; Stage IV Prostate Adenocarcinoma AJCC v7
    Interventions
    Carboplatin; Docetaxel; Laboratory Biomarker Analysis; Rucaparib Camsylate; Rucaparib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2018-08-24
    Completion
    2025-06-04
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionATM Gene Mutation; BRCA1 Gene Mutation; BRCA2 Gene Mutation; Castration Levels of Testosterone +6 more
    InterventionCarboplatin; Docetaxel; Laboratory Biomarker Analysis; Rucaparib Camsylate +1 more
    PhasePhase 2
    Registry statusTerminated

  • Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

    NCT03552471 · start 2018-07-12

    Registered record
    Registry ID
    NCT03552471
    Conditions
    BRCA1 Gene Mutation; BRCA2 Gene Mutation; Folate Receptor Alpha Positive; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma; Recurrent Uterine Serous Carcinoma; Recurrent Uterine Carcinosarcoma; Platinum Resistant Ovarian Cancer
    Interventions
    Laboratory Biomarker Analysis; Mirvetuximab Soravtansine; Pharmacokinetic Study; Rucaparib Camsylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-07-12
    Completion
    2022-12-19
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBRCA1 Gene Mutation; BRCA2 Gene Mutation; Folate Receptor Alpha Positive; Recurrent Fallopian Tube Carcinoma +6 more
    InterventionLaboratory Biomarker Analysis; Mirvetuximab Soravtansine; Pharmacokinetic Study; Rucaparib Camsylate
    PhasePhase 1
    Registry statusCompleted

  • Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor

    NCT03521037 · start 2018-02-27

    Registered record
    Registry ID
    NCT03521037
    Conditions
    Neoplasms
    Interventions
    Rucaparib camsylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-02-27
    Completion
    2021-02-24
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms
    InterventionRucaparib camsylate
    PhasePhase 1
    Registry statusCompleted

  • Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib

    NCT02986100 · start 2016-11

    Registered record
    Registry ID
    NCT02986100
    Conditions
    Solid Tumor
    Interventions
    C-14 labeled Rucaparib; Rucaparib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-11
    Completion
    2018-09
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumor
    InterventionC-14 labeled Rucaparib; Rucaparib
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetic Drug-Drug Interaction Study of Rucaparib

    NCT02740712 · start 2016-04

    Registered record
    Registry ID
    NCT02740712
    Conditions
    Neoplasms
    Interventions
    Caffeine; Warfarin; Omeprazole; Midazolam; digoxin; Vitamin K; Rucaparib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-04
    Completion
    2019-09
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms
    InterventionCaffeine; Warfarin; Omeprazole; Midazolam +3 more
    PhasePhase 1
    Registry statusCompleted